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Diagnosticul modern al hipertensiunii pulmonare arteriale
Lucrarea reprezintă o sinteză a cercetărilor actuale din domeniul diagnosticului modern al hipertensiunii pulmonare arteriale. Datele analizate 
provin dintr-o bibliografie bogată din literatura de specialitate. La etapa actuală, diagnosticarea sindromului de hipertensiune pulmonară arterială 
se realizează cu utilizarea diferitelor metode: electrocardiografia, ecocardiografia Doppler, radiografia toracică, scintigrafia pulmonară prin 
perfuzie şi prin ventilaţie, tomografia computerizată, testele funcţiei pulmonare şi cateterizmul cardiac. De asemenea, articolul conţine informaţii 
practice referitoare la rolul diferitelor metode imagistice în aprecierea patologiei.
Cuvinte-cheie: hipertensiunea pulmonară arterială, metode de diagnostic.
Современная диагностика легочной артериальной гипертензии
представленная работа является синтезом актуальных методов диагностики легочной артериальной гипертензии. Анализируемые 
данные селектированы из множества литературных источников данного профиля. В настоящее время диагностика синдрома легочной 
артериальной гипертензии осуществляется с использованием различных методов: электрокардиография, эхокардиография Допплер, 
рентгенография грудной клетки, перфузионная и вентиляционная сцинтиграфия легких, компьютерная томография, методы 
функциональной диагностики, катетеризация сердца. Статья также содержит практическую информацию о роли различных методов 
лучевой диагностики в определении соответствующей патологии.
Ключевые слова: легочная артериальная гипертензия, методы диагностики.
Introduction
Pulmonary hypertension is a serious disease with a poor 
prognosis. Pulmonary hypertension is defined by a mean pul-
monary arterial pressure of over 25 mm Hg at rest and of over 
30 mm Hg during activity. According to the recent 2003 WHO 
classification, pulmonary hypertension can be categorized as 
pulmonary arterial hypertension, pulmonary venous hyperten-
sion, hypoxic pulmonary hypertension, chronic thromboembolic 
pulmonary hypertension, or pulmonary hypertension from other 
causes. Pulmonary arterial hypertension is characterized his-
topathologically by vasoconstriction, vascular proliferation, in 
situ thrombosis and the remodeling of all 3 levels of the vascular 
walls. These pathologic changes result in progressive increases in 
the mean pulmonary artery pressure and in pulmonary vascular 
resistance, which, if left untreated, leads to right-ventricular 
failure and death. Early on in the disease progress, the signs and 
symptoms of PAH are often nonspecific, making diagnosis a 
challenge. Patients often show signs of progressively worsening 
dyspnea and fatigue. Patients with severe pulmonary arterial 
hypertension die of right heart failure. 
Diagnostic procedures include clinical history and 
physical examination, a standard chest radiography, elec-
trocardiography, transthoracic Doppler echocardiography, 
pulmonary function tests, arterial blood gas analysis, ven-
tilation and perfusion lung scan, high-resolution computed 
tomography of the lungs, contrast-enhanced spiral computed 
tomography of the lungs and pulmonary angiography, blood 
tests and immunology, abdominal ultrasound scan, exercise 
capacity assessment, and hemodynamic evaluation. Invasive 
and non-invasive markers of the severity of the disease, either 
biomarkers or physiological parameter, and tests that can be 
widely applied, have been proposed to reliably monitor the 
clinical course. Pulmonary biopsy is rarely indicated. Trans-
thoracic echocardiography is a key screening tool in the diag-
nostic algorithm. Because transthoracic echocardiography is 
an inexpensive, easy, and reproducible method, it is the most 
commonly used noninvasive diagnostic tool to determine 
pulmonary arterial pressure. It not only provides an estimate 
of pulmonary pressure at rest and during exercise, but may also 
help to exclude any secondary causes of pulmonary hyperten-
sion, predict the prognosis, monitor the efficacy of specific 
therapeutic interventions, and detect the preclinical stage of 
the disease. In addition, the measurement of serum markers, 
such as brain natriuretic peptide (BNP) are diagnostically 
useful and of prognostic significance.
Once the diagnosis and etiology of pulmonary hyper-
tension have been established, several parameters can predict 
its outcome in patients: functional class, right ventricular 
function, pulmonary hemodynamics, and certain laboratory 
parameters. Also, exercise parameters such as distance walk-
ing, peak oxygen uptake, or peak systolic blood pressure, can 
predict a reliable prognosis in patients.
Classification of Pulmonary Hypertension
Pulmonary hypertension was previously divided into 
primary and secondary categories; primary pulmonary 
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hypertension described an idiopathic hypertensive vas-
culopathy, exclusively affecting pulmonary circulation, 
whereas secondary pulmonary hypertension was associ-
ated with a causal underlying disease process (2, 3). The 
diagnosis of primary pulmonary was one of exclusion 
after ruling out all causes of pulmonary hypertension (4). 
The recent identification of a gene responsible for the 
inherited forms of this disease, along with the develop-
ment of specific medical treatments and the refinement of 
surgical techniques, has prompted a revised classification 
of pulmonary hypertension (5). In 2003, the Third World 
Symposium on pulmonary arterial hypertension held in 
Venice, Italy decided to maintain the general architecture 
and philosophy of the Evian – France classification (1998) 
and to propose some modifications. The aim of the modi-
fications was to make the “Venice clinical classification” 
more comprehensive, easier to follow, and more widespread 
as a tool of classification (1).
Clinical classification of Pulmonary Hypertension (PH) 
– Venice 2003.
1. Pulmonary arterial hypertension (PAH)
1.1. Idiopathic (IPAH)
1.2. Familial (FPAH)
1.3. Associated with (APAH):
1.3.1. Connective tissue disease
1.3.2. Congenital systemic to pulmonary shunts
1.3.3. Portal hypertension
1.3.4. HIV infection
1.3.5. Drugs and toxins
1.3.6. Other (thyroid disorders, glycogen storage disease, 
Gaucher’s disease, hereditary haemorrhagic telangiecta-
sia, haemoglobinopathies, myeloproliferative disorders, 
splenectomy)
1.4. Associated with significant venous or capillary in-
volvement
1.4.1. Pulmonary veno-occlusive disease (PVOD)
1.4.2. Pulmonary capillary haemangiomatosis (PCH)
1.5. Persistent pulmonary hypertension of the newborn 
(PPHN)
2. Pulmonary hypertension associated with left heart 
diseases
2.1. Left-sided atrial or ventricular heart disease
2.2. Left-sided valvular heart disease
3. Pulmonary hypertension associated with lung 
respiratory diseases and/or hypoxia
3.1. Chronic obstructive pulmonary disease
3.2. Interstitial lung disease
3.3. Sleep-disordered breathing
3.4. Alveolar hypoventilation disorders
3.5. Chronic exposure to high altitudes
3.6. Developmental abnormalities
4. Pulmonary hypertension due to chronic thrombotic 
and/or embolic disease
4.1. Thromboembolic obstruction of proximal pulmonary 
arteries
4.2. Thromboembolic obstruction of distal pulmonary 
arteries
4.3. Non-thrombotic pulmonary embolism (tumour, 
parasites, foreign material)
5. Miscellaneous
Sarcoidosis, histiocytosis X, lymphangiomatosis, com-
pression of pulmonary vessels (adenopathy, tumour, fibrosing 
mediastinitis)
Definition and clinical symptoms
In its early stages, pulmonary arterial hypertension may 
be asymptomatic. Pulmonary hypertension often presents 
itself with nonspecific symptoms. The most common symp-
toms – exertional dyspnea, fatique, and syncope – reflect an 
inability to increase cardiac output during activity. The leading 
symptom of pulmonary arterial hypertension is exertional 
dyspnea. A minority of patients may report typical angina 
despite normal coronary arteries. The symptoms of pulmo-
nary hypertension can also include weakness and abdominal 
distension (7). Hemoptysis resulting from the rupture of dis-
tended pulmonary vessels is a rare but potentially devastating 
event. Raynaud`s phenomenon occurs in approximately 2% of 
patients with primary pulmonary hypertension, but it is more 
common in patients with pulmonary hypertension related to 
connective tissue disease. More specific symptoms may reflect 
the underlying cause of pulmonary hypertension (8). Symp-
toms at rest are reported only in very advanced cases.
Diagnostics
The clinical cardinal symptom of pulmonary hyper-
tension is dyspnea. The diagnostic process of pulmonary 
hypertension requires a series of investigations that are in-
tended to make the diagnosis, to clarify the clinical class of 
pulmonary hypertension and the type of pulmonary arterial 
hypertension, and to evaluate functional and hemodynamic 
impairment (Table 1).
Table 1
Diagnosis of pulmonary hypertension
NON-INVASIVE
Echocardiography transthoracic
Walking distance of 6 minutes: for severity code, therapy control and 
prognosis
Laboratory tests
Pulmonary function: spirometry
Spiroergometry
Ventilation-perfusion lung scan
Computer tomography of the lung: interstitial tissue visualization
INVASIVE
Right cardiac catheterization
Pharmacological tests
Non-invasive diagnostics
Physical examination. Physical examination can reveal 
increased jugular venous distention, a tricuspid regurgitant 
holosystolic murmur, and a loud P2; all suggestive of elevated 
right-sided pressure. Lung sounds are usually normal. Hepa-
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tomegaly, peripheral oedema, ascites and cool extremities, 
characterize patients at a more advanced stage of the disease 
with right ventricular failure at rest. 
Electrocardiography. Electrocardiographic signs of the 
right heart include right axis deviation, right ventricular hy-
pertrophy, and peaked P waves. However, electrocardiography 
lacks sufficient diagnostic accuracy to serve as a screening 
tool for the detection of pulmonary arterial hypertension. 
Right ventricular hypertrophy on ECG is present in 87% of 
patients and right axis deviation in 79% of patients (7). ECG 
has inadequate sensitivity (55%) and specifity (70%) (10). A 
normal ECG does not exclude the presence of severe pulmo-
nary hypertension.
Chest radiography. The chest radiograph is inferior 
to ECG in detecting pulmonary hypertension, but it may 
show evidence of underlying lung disease (3). In 90% 
of pulmonary arterial hypertension patients, the chest 
radiograph is abnormal at the time of diagnosis (7). The 
findings include central pulmonary arterial dilatation 
which contrasts with “pruning” of the peripheral blood 
vessels. A hilar-to-thoracic ratio greater than 0.44, a right 
descending pulmonary artery diameter of greater than 18 
mm, and right atrial and ventricular enlargement may be 
seen, which progresses in more advanced cases. However, a 
normal chest radiograph does not exclude mild pulmonary 
hypertension, including left-heart disease or pulmonary 
veno-occlusive disease.
Echocardiography. Transthoracic echocardiography 
is an excellent non-invasive screening test for patients with 
suspected pulmonary hypertension. Transthoracic echocar-
diography estimates pulmonary artery systolic pressure and 
can provide additional information about the causes and 
consequences of pulmonary hypertension. 
Pulmonary artery systolic pressure is equivalent to 
right ventricular systolic pressure in the absence of pul-
monary outflow obstruction. With CW-Doppler-echo-
cardiography, right ventricular systolic pressure (RVSP) 
can be obtained by adding the estimated right atrial 
pressure (RAP) to the pressure gradient derived from 
systolic regurgitant tricuspid flow velocity v, according 
to the formula: RVSP = 4 v2 + RAP. Echocardiographic 
estimation of the right atrial pressure can be attained 
by measuring the diameter of the inferior vena cava and 
the respiratory motion of the inferior vena cava (Table 
2). According to the normal ranges of Doppler-derived 
values of pulmonary artery pressures, mild pulmonary 
hypertension can be defined as pulmonary artery sys-
tolic pressures of approximately 36-50 mmHg or resting 
tricuspid regurgitant velocity of 2.8-3.4 m/sec, assum-
ing a normal right atrial pressure of 5 mmHg. The right 
ventricular systolic pressure may be underestimated in 
some cases because of suboptimal tracings of the regurgi-
tation jet, of decreased tricuspid regurgitant jet velocity 
due to high right atrial pressures, and poor estimation 
of right atrial pressures. However, in order to estimate a 
right ventricular systolic pressure by echocardiography, 
tricuspid regurgitation must be present.
Table 2
Echocardiographic estimation of the right atrial pressure 
(RAP) by measuring the diameter of the inferior vena cava 
and the respiratory motion of the vena cava inferior (VCI)
VCI-diameter (cm) Respiratory motion (%) RAP (mmHg)
<1,5 100 <5
1,5-2,5 >50 5-10
1,5-2,5 <50 10-15
>2,5 >50 15-20
>2,5 + dilated 0 >20
Hepatic vein – –
Indirect signs of pulmonary hypertension are: 
paradoxical septal motion (septal bowling or flattering), 
decreased or missing collapse of the vena cava inferior, 
pericardial effusion, right ventricular hypertrophy and 
reduced right ventricular ejection time. Additional exami-
nation to the routine echocardiography is the estimation 
of right ventricular Tei-index (isovolumetric contraction 
time and relaxation time/ejection time) (4) and the “tricus-
pid annular plane systolic excursion” (TASPE). The peak 
early diastolic pulmonary regurgitation velocity is useful 
in estimating mean pulmonary artery pressure (mean 
PAP). Together with the dimension of the right atrium and 
pericardial effusion, Tei-index and TASPE are important 
prognostic parameters in patients with pulmonary hyper-
tension, while the right ventricular systolic pressure does 
not correlate with survival (10). Echocardiography is the 
most useful imaging modality for detecting pulmonary 
hypertension and excluding underlying cardiac disease.
Ventilation/Perfusion Scanning. Ventilation/per-
fusion scans are often used to rule out other causes of 
dyspnea. Fortunately, ventilation-perfusion lung scanning 
is a reliable method for differentiating chronic thrombo-
embolism from primary pulmonary hypertension (9). Nor-
mal ventilation and quantification scans rule out chronic 
thromboembolic disease (10). The finding of one or more 
segmental or larger perfusion defects is a sensitive marker 
of embolic obstruction.
Computer Tomography. Computerized tomographic 
(CT) scanning of the chest with high-resolution images is 
useful in excluding occult interstitial lung disease and medi-
astinal fibrosis. It also is helpful in the diagnosis of pulmonary 
embolism. Magnetic resonance imaging can be used to assess 
the size and function of the right ventricle, myocardial thick-
ness, the presence of chronic thromboembolic disease with 
a mosaic pattern of the lung parenchyma, and cardiac and 
pulmonary pressures (6, 7).
Pulmonary Function Testing. The role of pulmonary 
function testing is to rule out parenchymal or obstructive 
lung disease as a cause of the patient`s symptoms. Unless 
hypoxia is present, pulmonary hypertension cannot be 
attributed to these disorders until pulmonary function is 
severely reduced. Some patients with pulmonary artery 
hypertension can suffer a mild decline in their total lung 
capacity and diffusing capacity for carbon monoxide, but 
the severity of these declines does not correlate with dis-
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ease severity. With pulmonary function testing, neither an 
accurate diagnosis nor adequate follow-up examinations 
are possible.
Six-minute Walk Test. Submaximal testing with a 6-
minute walk test is recommended at the time of diagnosis to 
establish baseline functional impairment and at the follow-up 
to assess response to therapy and prognosis (8). The mortality 
risk is increased 2.4-fold in patients with pulmonary arterial 
hypertension who are able to walk less than 300 m in 6 min-
utes and 2.9-fold in those with a greater than 10% decline in 
arterial oxygen saturation (14). The 6-minute walk distance 
correlates with severity by NYHA functional class in patients 
with pulmonary hypertension. Patients who walk less than 
332 m have a significantly lower survival rate than those who 
walk farther (10).
Cardiopulmonary Exercise Testing. Cardiopulmonary 
exercise testing (CPET) allows the measurement of ventilation 
and pulmonary gas exchange during exercise testing, provid-
ing additional “pathophysiologic” information to that derived 
from standard exercise testing. Cardiopulmonary exercise 
testing has no added value in the initial diagnostic testing of 
pulmonary hypertension. The most important parameters 
are the maximal oxygen uptake (peak VO2) and the rela-
tion from ventilation to CO2-relief (VE/VCO2). Pulmonary 
hypertension patients show reduced peak O2, reduced peak 
work rate, reduced ratio of VO2 increase to work rate increase, 
reduced anaerobic threshold and reduced peak oxygen pulse; 
they show also increased VE and VCO2 slope representative 
of ventilatory inefficiency (13).
Invasive diagnostics
Right Heart Catheterization. Right heart catheteriza-
tion remains the gold standard for the diagnosis of pulmonary 
hypertension. All patients suspected of having significant 
pulmonary hypertension after clinical and transthoracic 
echocardiographic evaluation should undergo right heart 
catheterization, particularly if they are candidates for treat-
ment (6).
The goals of right heart catheterization, in addition to 
making a diagnosis, are to measure right atrial and ventricular 
pressures, to detect pulmonary artery pressure (PAP systolic, 
PAP diastolic, PAP mean) and pulmonary artery capillary 
wedge pressure (PCWP), to measure pulmonary vascular and 
systemic vascular resistance (PVR, SVR), to calculate cardiac 
output/index (end organ function) by Fick principle or ther-
modilution, to evaluate pulmonary artery O2-saturation, and 
to look for the presence of left-to-right shunts and right-to-
left shunt (the latter makes left heart cardiac catheterization 
necessary). The significance of right heart catheterization is 
to assess the severity of the hemodynamic impairment, to 
predict the prognosis, to identify other causes of pulmonary 
hypertension, to monitor the etiopathology, to evaluate the 
right ventricular function, and to test the vasoreactivity of the 
pulmonary circulation. 
Vasodilator testing during right-heart cardiac catheter-
ization should only be done by using short-acting vasodilators 
such as adenosine/epoprostenol intravenously or by admin-
istering prostacyclin, nitric oxide or iloprost by inhalation. 
According to the European Society of Cardiology, a response 
to acute vasodilator testing includes a decrease of more than 
10 mmHg in the mean pulmonary artery pressure and/or a 
decrease of the mean pulmonary artery pressure under 40 
mmHg. Responders to acute vasodilator testing have a favor-
able clinical response and course when treated with calcium 
channel blockers, but calcium channel blockers should be 
strictly avoided in non-responders. There are no absolute 
contraindications to right heart catheterization and complica-
tions are rare, though may happen.
Disease monitoring
While echocardiography is the screening method for 
acquisition of pulmonary hypertension (high sensitivity), the 
right heart cardiac catheterization has a higher specificity and 
is a required method to confirm the diagnosis definitely. Some 
patients with mild and moderate pulmonary hypertension can 
be managed without right heart catheterization. Those with 
mild to moderate pulmonary hypertension due to chronic 
hypoxemia (resting, exertional or noctural) can be followed 
with serial echocardiography for evidence of progression on 
appropriate oxygen and/or noctural ventilatory support. For 
patients with mild to moderate pulmonary hypertension by 
echocardiography who do not have NYHA class III symp-
toms, right heart cardiac catheterization can be reserved as a 
future option if pulmonary hypertension progresses on serial 
echocardiography every 3 to 6 months.
Right heart function and ejection fraction are of great 
importance in patients with pulmonary hypertension: clini-
cal severity and mortality rate do increase in concert with 
the degree of limitation of the right ventricular function and 
ejection fraction. The higher the mean pulmonary arterial 
pressure and the pulmonary wedge pressure and the worse the 
right ventricular function, the higher the mortality with left 
heart insufficiency will be. Patients with a low ejection frac-
tion and high pulmonary artery pressure show a particularly 
bad prognosis, independent of the degree of restricted left 
ventricular function (11, 12).
Conclusion
Pulmonary hypertension is defined as an elevation in 
pulmonary arterial pressures and is characterized by symp-
toms of dyspnea, chest pain and syncope. If left untreated, 
pulmonary arterial hypertension has a high mortality rate, 
typically from decompensated right-sided heart failure. Esti-
mated median survival is approximately 2.8 years.
The past decade has seen major advances in our under-
standing of the pathophysiological mechanisms underlying 
the development of pulmonary arterial hypertension. The 
diagnosis is now more clearly defined according to a new 
clinical classification, and clear algorithms have been devised 
for the investigation. Imaging methods are very important for 
the diagnosis of pulmonary arterial hypertension. However, 
the prognosis of pulmonary arterial hypertension remains 
guarded despite recent advances and new therapeutic op-
tions.
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Terapia antiinflamatoare la bolnavii cu bronhopneumopatie  
obstructivă cronică
S. Butorov, V. Gonciar, I. Ţîbîrnă, A. Cojocaru, C. Scutari
Catedra Farmacologie şi Farmacologie clinică, USMF „Nicolae Testemiţanu”
Anti-Inflammatory Therapy in the Treatment of Patients with Obstructive Pulmonary Disease
The aim of the study was to investigate the effects of Eurespal (Fenspirid) on the clinical manifestations and parameters of inflammation 
in patients with chronic obstructive pulmonary disease (COPD). The two stages of the study included a 3-week treatment during exacerbation 
periods and a 3-month outpatient follow-up during clinical remission periods. During exacerbation periods of COPD the researchers observed 
earlier and more noticeable antitussive and mucolytic action of Eurespal which were associated with the lessening of bronchial obstruction and 
inflammation, a significant drop of the C-reactive protein level and an increase of total oxidant serum level. Long-term (3 months) treatment 
with Eurespal led to further positive dynamics of clinical and laboratory indices of inflammation. The results of the study demonstrate that 
inclusion of Eurespal in complex therapy of COPD increases efficacy of treatment through its anti-inflammatory action during the periods of 
exacerbation and relative remission.
Key words: Eurespal, chronic obstructive pulmonary disease, inflammation.
Противовоспалительная терапия в лечении больных хронической обструктивной болезнью легких
Было изучено влияние эреспала (фенспирид) на клиническое течение и показатели воспаления у больных хронической 
обструктивной болезнью легких (ХОБЛ). Исследование проводили в 2 этапа: в течение 3 нед терапии при обострении заболевания и 
на протяжении 3 мес амбулаторного лечения в периоде клинической ремиссии. при обострении ХОБЛ терапия эреспалом оказывала 
более ранний и отчетливый противокашлевой, муколитический эффекты, сопровождаясь уменьшением обструкции, интенсивности 
воспаления в бронхах, достоверным снижением содержания С-реактивного белка и увеличением содержания общих антиоксидантов 
в сыворотке крови. Длительное (в течение 3 мес) лечение эреспалом обеспечивало у больных ХОБЛ дальнейшую положительную 
динамику клинико-лабораторных показателей воспаления. Результаты исследования позволяют считать, что включение эреспала в 
комплексную терапию ХОБЛ повышает эффективность лечения как при обострении, так и ремиссии заболевания, оказывая выраженное 
противовоспалительное действие.
Ключевые слова: Эреспал, хроническая обструктивная болезнь легких, воспаление.
Introducere
Boala pulmonară bronhopneumopatia obstructivă 
cronică (BPOC) este o problemă actuală a ocrotirii sănătăţii 
şi una dintre cauzele de bază în mortalitatea cauzată de bolile 
pulmonare. BPOC exercită o influenţă semnificativă asupra 
calităţii vieţii şi longevităţii pacienţilor şi cauzează pierderi 
